EGFR and breast cancer: The neurotensinergic system also favored the overexpression of HER2/3 and EGFR in BC and, in an experimental model of BC, the growth of BC cells overexpressing neurotensin/neurotensin receptor 1 was blocked with lapatinib (an HER2/EGFR tyrosine kinase inhibitor) or metformin [216].